Assessment of minimal residual disease in standard-risk AML

New England Journal of Medicine

Volumn 374, Issue 5, 2016, Pages 422-433

  Ivey, Adam ^a   Hills, Robert K ^e   Simpson, Michael A ^b   Jovanovic, Jelena V ^b   Gilkes, Amanda ^e   Grech, Angela ^f   Patel, Yashma ^c   Bhudia, Neesa ^d   Farah, Hassan ^b   Mason, Joanne ^g   Wall, Kerry ^g   Akiki, Susanna ^g   Griffiths, Michael ^g   Solomon, Ellen ^b   McCaughan, Frank ^b   Linch, David C ^c   Gale, Rosemary E ^c   Vyas, Paresh ^h   Freeman, Sylvie D ⁱ   Russell, Nigel ^j   Burnett, Alan K ^e   Grimwade, David ^a,b   more..

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g West Midlands Regional Genetics Laboratory   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEOPHOSMIN; DNA; NUCLEAR PROTEIN; TRANSCRIPTOME;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NPM1 GENE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; EXOME; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR;

BASE SEQUENCE; DNA, NEOPLASM; EXOME; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TRANSCRIPTOME;

EID: 84956917285     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1507471     Document Type: Article

References (40)

1. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-9.
2. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
3. Grimwade D, Ivey I, Huntly BJP. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 2016; 127: 29-41.
4. Döhner H, Estey EH, Amadori S, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
5. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579-90.
6. National Comprehensive Cancer Network AML guidelines (http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#aml).
7. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-66.
8. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18.
9. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-33.
10. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30: 742-50.
11. Gale RE, Lamb K, Allen C, et al. Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol 2015; 33: 2072-83.
12. Peterlin P, Renneville A, Ben Abdelali R, et al. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica 2015; 100(5): e196-9.
13. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-89.
14. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-72.
15. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood 2014; 124: 3345-55.
16. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006; 20: 1103-8.
17. Chou WC, Tang JL, Wu SJ, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 998-1004.
18. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-31.
19. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29: 2709-16.
20. Shayegi N, Kramer M, Bornhäuser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013; 122: 83-92.
21. Hubmann M, Köhnke T, Hoster E, et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 2014; 99: 1317-25.
22. Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 2014; 5: 6280-8.
23. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014; 111: 2548-53.
24. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-33.
25. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015; 125: 3878-85.
26. Burnett AK, Hills RK, Wheatley K, Goldstone AH, Prentice AG, Milligan D. A sensitive risk score for directing treatment in younger patients with AML. Blood 2006; 108: 18. abstract.
27. Ling V, Burnett AK, Bradstock K, Seymour JF, Hills RK, Wei A. Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. Br J Haematol 2013; 160: 861-3.
28. Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or nonintensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 2014; 28: 1953-9.
29. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650-8.
30. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17: 2318-57.
31. Kühnl A, Valk PJ, Sanders MA, et al. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood 2015; 125: 2985-94.
32. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 2014; 124: 273-6.
33. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-9.
34. Raghavan M, Smith LL, Lillington DM, et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008; 112: 814-21.
35. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-65.
36. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia 2014; 28: 1949-52.
37. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-91.
38. Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2014; 2014: 244-9.
39. Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122: 100-8.
40. Pløen GG, Nederby L, Guldberg P, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol 2014; 167: 478-86.